Skip to main content
. 2018 May 18;18(2):135–147. doi: 10.3727/105221618X15174108894682

Figure 5.

Figure 5

EMD1214063 reduces cell proliferation after 8 and 11 weeks of treatment of Met-β-catenin mice, which is associated with a decrease in cyclin D1 levels. (A) IHC for Ki-67 and PCNA shows decrease in the EMD1214063 treatment group compared with the control group at both 8 and 11 weeks after treatment. Cyclin D1 levels were also reduced. No change in the number of TUNEL+ cells was evident after EMD1214063 treatment at either time point. (B) Quantification of TUNEL, Ki-67, and PCNA immunohistochemistry shows insignificant difference in apoptosis, but significant differences in Ki-67 at combined time points (***p = 0.0004), at 8 weeks (**p = 0.0096), and at 11 weeks (*p = 0.042), as well as PCNA at combined time points (**p = 0.0016) or at 8 weeks (*p = 0.0225). (C) Quantification of cyclin D1 staining showed a significant difference in EMD1214063-treated samples compared to controls at both times combined (***p < 0.0001), at 8 weeks (*p = 0.0330), and at 11 weeks (**p = 0.0028). (D) Decrease in levels of cyclin D1 after EMD1214063 was verified by Western blots as well. GAPDH shows comparable loading in all lanes.